Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes

Multicenter, Open Label, Non-randomized, Non-interventional Observational Study of Safety of Treatment Initiation With a Biphasic Insulin Aspart (NovoMix® 30) in Hospitalized Patients With Type 2 Diabetes Mellitus

This study is conducted in Europe. The aim of this study is to evaluate the safety and efficacy of biphasic insulin aspart (NovoMix® 30) in hospitalised patients with type 2 diabetes with the aim of intensifying their treatment.

Inclusion Criteria:

• Patients with type 2 diabetes
• Treated with oral anti-diabetics and/or human insulin

Exclusion Criteria:

• Persons previously included in the trial
• Hypersensitive to biphasic insulin aspart or any of the excipients
• Pregnant or lactating women, or those who plan to get pregnant within the next 12 months